Holen Sie sich die Stockscreener-App
1.97
1.50%
-0.03
Handel nachbörslich:
1.94
-0.03
-1.52%
Schlusskurs vom Vortag:
$2.00
Offen:
$1.95
24-Stunden-Volumen:
30,034
Relative Volume:
2.36
Marktkapitalisierung:
$3.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+13.87%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.9452
$2.04
1-Wochen-Bereich:
$1.6313
$2.14
52-Wochen-Spanne:
$1.6313
$2.14
Vivosim Labs Inc Stock (VIVS) Company Profile
Firmenname
Vivosim Labs Inc
Sektor
Branche
Telefon
858-224-1000
Adresse
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie VIVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.97 | 3.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-12-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-11-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | Eingeleitet | Raymond James | Outperform |
| 2015-08-11 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | Eingeleitet | Jefferies | Buy |
| 2015-06-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Vivosim Labs Inc Aktie (VIVS) Neueste Nachrichten
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Eli Lilly stock rises after deal with Organovo (ONVO:NASDAQ) - Seeking Alpha
ONVO Stock Quote Price and Forecast - CNN
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Finanzdaten der Vivosim Labs Inc-Aktie (VIVS)
Es liegen keine Finanzdaten für Vivosim Labs Inc (VIVS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):